1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21844
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBatistatou, A.en
dc.contributor.authorStefanou, D.en
dc.contributor.authorGoussia, A.en
dc.contributor.authorArkoumani, E.en
dc.contributor.authorPapavassiliou, A. G.en
dc.contributor.authorAgnantis, N. J.en
dc.date.accessioned2015-11-24T19:18:07Z-
dc.date.available2015-11-24T19:18:07Z-
dc.identifier.issn0171-5216-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21844-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAstrocytoma/*chemistry/*pathologyen
dc.subjectBrain Chemistryen
dc.subjectBrain Neoplasms/*chemistry/*pathologyen
dc.subjectChilden
dc.subjectEstrogen Receptor beta/*analysisen
dc.subjectFemaleen
dc.subjectGene Expression Regulation, Neoplasticen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPredictive Value of Testsen
dc.subjectTumor Markers, Biological/*analysisen
dc.titleEstrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasmen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00432-004-0548-9-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15141349-
heal.identifier.secondaryhttp://www.springerlink.com/content/5vgu7k5hm9603pq5/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2004-
heal.abstractPURPOSE: Estrogen receptor beta (ERbeta) is the second identified receptor mediating the effects of estrogen on target tissues. The role of ERbeta in cancer pathobiology is largely unknown, because specific antibodies have not been available until recently. Initial studies have shown that ERbeta expression declines in breast, ovarian, prostatic, and colon carcinomas. Tamoxifen, a synthetic anti-estrogen compound that is a mixed agonist/antagonist of estrogen receptor alpha (ERalpha) and a pure antagonist of ERbeta, has moderate beneficial effects in human astrocytic neoplasms. However, most published studies agree that glial tumors do not express ERalpha. The purpose of this study was to explore the expression of ERbeta in astrocytic neoplasms. METHODS: ERbeta expression was monitored immunohistochemically in 56 cases of astrocytomas of all grades (grade I-IV) and in adjacent non-neoplastic brain tissue. RESULTS: Moderate or strong nuclear immunopositivity was obtained in non-neoplastic astrocytes and in low-grade astrocytomas, whereas the majority of high-grade tumors were immunonegative or displayed weak immunoreactivity. The progressive decline in ERbeta expression paralleled the increase in tumor grade. CONCLUSIONS: In as much as ERbeta is possibly the only ER expressed in astrocytes, its decreased expression may play an important role in astrocytic tumor initiation and in the potential response of glial neoplasms to tamoxifen.en
heal.journalNameJ Cancer Res Clin Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Batistatou-2004-Estrogen receptor be.pdf1.6 MBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons